Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

Shots:

• Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B
• The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration
• Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS
  
  Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly